100 results
8-K
EX-99.1
CTMX
CytomX Therapeutics Inc
8 May 24
CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for
4:41pm
. “These data build on more than a decade of innovation at CytomX, and, we believe, open broad new possibilities for T-cell engagers across many targets
8-K
EX-99.1
CTMX
CytomX Therapeutics Inc
8 May 24
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
4:04pm
targets and cancer types. CX-2051 has demonstrated a wide predicted therapeutic index in multiple preclinical models, constituting an opportunity for broad … completion of existing targets under the BMS, Moderna and Regeneron agreements as well as the $10.0 million of milestones earned under
8-K
EX-99.1
37xv78m4q
11 Mar 24
CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update
4:02pm
8-K
EX-99.1
43pedlw2m1jbzy
7 Nov 23
CytomX Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
4:05pm
424B3
vbm4ymufwy7
25 Aug 23
Prospectus supplement
5:36pm
8-K
EX-99.1
fxqljk5r
8 Aug 23
CytomX Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
4:08pm
8-K
EX-99.1
ib7t8xn z3fv3
9 May 23
CytomX Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
4:12pm
8-K
EX-99.1
4wa7r04f1
8 Nov 22
CytomX Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
4:09pm